Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum

Blok, J. L.; Li, K.; Brodmerkel, Carrie; Horvatovich, Péter; Jonkman, Marcel F.; Hórvath, Barbara

doi:10.1111/bjd.14338

Cited by 178 publications

(169 citation statements)

References 37 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…Studies of inflammatory serum markers in HS are scarce. Blok et al [30] studied the evolution of serum levels of IL-2R, TNF- α , IL17A, and IL17F in 12 patients who were treated with ustekinumab, a monoclonal antibody against IL-12/23 p40, and they did not observe an elevation of these inflammatory markers or changes with treatment. Matusiak et al [31] studied the serum TNF- α levels of 54 patients with HS and observed significantly higher levels in the HS patients compared with the healthy controls.…”

Section: Discussionmentioning

confidence: 99%

The Clinical Significance of Increased Serum Proinflammatory Cytokines, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Patients with Hidradenitis Suppurativa

Jiménez‐Gallo

Varga-Martínez

Ossorio-García

et al. 2017

Mediators of Inflammation

View full text Add to dashboard Cite

Objectives To assess inflammatory serum markers including serum proinflammatory cytokines, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) according to the clinical inflammatory activity of patients with hidradenitis suppurativa (HS). Patients and Methods Seventy-four patients with HS were studied based on the Hidradenitis Suppurativa-Physician Global Assessment (HS-PGA) score and Hurley staging system. Proinflammatory cytokines were measured using a multiplex cytokine assay. Twenty-two healthy volunteers were recruited. Results Serum interleukin- (IL-) 6, IL-23, soluble tumour necrosis factor alpha (TNF-α) receptor I (sTNF-RI), CRP, and ESR were different in the patients with HS compared with those in the healthy controls (P < 0.05). The levels of IL-1β, IL-6, IL-8, IL-10, IL-12p70, IL-17A, sTNF-RII, CRP, and ESR were significantly elevated according to inflammatory activity based on HS-PGA scores (r > 0.25, P < 0.05). The levels of IL-6 (r = 0.53, P < 0.001), CRP (r = 0.54, P < 0.001), and ESR (r = 0.60, P < 0.001) were especially well correlated with clinical inflammatory activity based on HS-PGA scores. The levels of IL-6, IL-8, sTNF-RI, sTNF-RII, CRP, and ESR were significantly elevated according to Hurley staging system. Conclusions Serum proinflammatory cytokines, CRP, and ESR are increased in relation to the clinical inflammatory activity of patients with HS compared with healthy controls. Serum IL-6, CRP, and ESR are effective biomarkers for evaluating the severity of HS.

show abstract

Section: Discussionmentioning

confidence: 99%

The Clinical Significance of Increased Serum Proinflammatory Cytokines, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Patients with Hidradenitis Suppurativa

Jiménez‐Gallo

Varga-Martínez

Ossorio-García

et al. 2017

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…In period 2, the rates of serious adverse events were ≤4.6% in all the groups in both studies, with no significant differences between placebo and treatment groups. On the other hand, another biologic drug, ustekinumab, a monoclonal antibody directed against IL-12 and IL-23, has been shown to reduce the mean MSS with a 46.3% improvement in 12 patients with moderate to severe (Hurley stage II–III) disease treated with 45 or 90 mg ustekinumab (depending on body weight) at weeks 0, 4, 16, and 28 129. However, further studies are needed to evaluate its efficacy in HS patients because, apart from the study of Blok et al, its use in HS has been described only in case reports or very small case series 130–133…”

Section: Treatmentmentioning

confidence: 99%

Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment

Napolitano¹,

Megna²,

Тимощук³

et al. 2017

CCID

186

164

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease primarily affecting apocrine gland-rich areas of the body and presenting with painful nodules, abscesses, sinus tracts, and scarring. HS is a multifactorial disease in which genetic and environmental factors play a key role. The primary defect in HS pathophysiology involves follicular occlusion of the folliculopilosebaceous unit, followed by follicular rupture, and immune responses (perifollicular lympho-histiocytic inflammation), finally leading to the development of clinical HS lesions. HS has a destructive impact on the patient’s quality of life, being a very challenging disease. Available treatments are limited, mostly off-label and with high variability in the reported efficacy. Fortunately, a monoclonal antibody against tumor necrosis factor alpha has been recently approved for treatment of moderate to severe HS, offering patients a promising new option. This review focuses on the main features of HS, including epidemiology, clinical aspects, pathogenesis, severity classifications, comorbidities, and currently available treatments.

show abstract

“…Furthermore, none of the trials reported the percentage of patients that were Hispanic or stratified the responses to adalimumab by race. The majority of the efficacy trials investigating other systemic agents, including etanercept, infliximab, anakinra, and ustekinumab, either did not report race or had largely Caucasian cohorts [37-40]. Taken together, this highlights the underrepresentation of non-Caucasian subjects and the need for trials that enroll more HS patients with SOC and stratify results by racial subgroups (Table 2).…”

Section: Treatment Response In Socmentioning

confidence: 99%

Hidradenitis Suppurativa: Disease Burden and Etiology in Skin of Color

2017

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease. Although most studies on HS are conducted in largely Caucasian populations, evidence demonstrates a higher prevalence in patients with skin of color, including African and Hispanic populations. These racial subgroups are likely at risk for greater disease burden due to a higher prevalence of components of the metabolic syndrome, comorbid depression, and low socioeconomic status; however, there is a paucity of research in these populations. Additionally, studies examining the genetic and anatomical basis for HS, as well as the response to HS therapies, are lacking for patients with skin of color. Complicating this issue is the limited access to effective medical care, including dermatologists, for African and Hispanic populations as well as other minority groups. In this review, we identify gaps in the knowledge base, highlight the association between HS and patients with skin of color, and provide direction for much needed research into this condition.

show abstract

Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum

Abstract: The majority of patients improved with ustekinumab. Although no biomarker was discovered, low LTA4H concentrations with mild disease severity may be predictive of the effectiveness of ustekinumab.

Cited by 178 publications

References 37 publications

The Clinical Significance of Increased Serum Proinflammatory Cytokines, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Patients with Hidradenitis Suppurativa

The Clinical Significance of Increased Serum Proinflammatory Cytokines, C-Reactive Protein, and Erythrocyte Sedimentation Rate in Patients with Hidradenitis Suppurativa

Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment

Hidradenitis Suppurativa: Disease Burden and Etiology in Skin of Color

Contact Info

Product

Resources

About